OptimizeRx Corporation (OPRX)

From the record

OptimizeRx Corporation's filings since 2017 show 7 warning events of 2 kinds: an auditor change (8-K item 4.01, 4 times, the latest 2026-03-30); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2024-08-15) (its current reports).

From the record

OptimizeRx Corporation's 10 filed years say what it did: revenue went from $8 million in fiscal 2016 to $109 million in fiscal 2025, up 34.2% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 3 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, OptimizeRx Corporation's diluted share count grew about 1.4% a year, and dividends and buybacks returned about 46% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 2 sales and 0 purchases of their own stock on the open market in the year to 2026-10-02 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, OptimizeRx Corporation earned about 4 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 42 cents per dollar of everything the company owns. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 1.4% over the year (the filed statements).

From the record

OptimizeRx Corporation's standing among 101 graded names in its industry family: revenue of $109 million in fiscal 2025 ranks in the bottom 21% by size; a net margin of 4.7% ranks in the top 48%; revenue growth of 20.6% a year over the last 3 filed years ranks in the top 25% (its annual reports).

From the record

OptimizeRx Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Silvestro, Stephen L (Chief Executive Officer, as filed), filing under that title since 2025-08-25, 1.2 years (bottom 21% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 46%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 18%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

OptimizeRx Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $23 million against debt of $26 million leaves -1.7% of its assets as net cash, bottom 42% of its family; cash from operations less capital spending is 17% of revenue (top 30%); a gross margin of 67.3% (top 27%); research spending of 0% of revenue (bottom 1%) (its annual report).

From the record

OptimizeRx Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 20.6% a year over the last three filed years against 34.2% over all 10, slowing (bottom 22% of its family); the newest year grew 18.8% (top 28%); capital spending grew -10.5% a year (bottom 27%) (its annual reports). OptimizeRx Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

OptimizeRx Corporation's newest year against its own record: revenue of $109 million in fiscal 2025 came in 2.2% below the $112 million its prior three years' pace pointed to (bottom 48% of its family); net income of $5 million against a prior three-year average of $16 million (top 22%); a net margin of 4.7% against -21.6% before (top 23%) (its annual reports).